Skip to main content

Table 1 Patient characteristics

From: Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer

Patient

Age

(yrs)

Primary or

Recurrent

Metastatic site

Histologya

ER/PR/HER-2a

Ki-67a

Gradea

1

59

Recurrent

Bone, lymph node, other

Ductal

+/−/+

NA

III

2

47

Recurrent

Bone, lymph node

Ductal

+/+/−

10

I

3

40

Recurrent

Lung, liver, lymph node

Ductal

+/+/−

5

II

4

27

Primary

Lung, lymph node

Ductal

+/+/−

10

II

5

52

Recurrent

Bone, lymph node

Ductal

+/−/−

NA

NA

6

50

Recurrent

Bone, liver

Ductal

+/−/+

NA

II

7

54

Recurrent

Lung, lymph node

Ductal

−/−/−

NA

NA

8

62

Recurrent

Bone, other

Ductal

−/−/−

30

III

9

37

Recurrent

Bone

Ductal

+/+/−

40

II

10

48

Recurrent

Bone

Ductal

+/+/−

NA

II

11

67

Primary

Bone

NST

+/+/−

10

I

12

43

Recurrent

Bone

Ductal

−/−/−

NA

III

13

55

Recurrent

Lymph node

NST

+/+/+

NA

NA

14

38

Recurrent

Bone, lung, liver

Ductal

+/+/−

NA

N A

15

61

Primary

Bone, lung

NST

+/+/−

30

II

16

59

Recurrent

Bone

Ductal

+/−/−

10

III

17

52

Recurrent

Bone

Ductal

+/+/+

NA

NA

18

37

Recurrent

Bone, lung, liver, other

NST

+/+/+

50

III

19

50

Recurrent

Bone

Ductal

+/−/−

NA

NA

20

59

Recurrent

Other

Ductal

−/−/−

30

III

21

55

Recurrent

Bone, lung, liver

Ductal

−/−/−

20

II

22

57

Recurrent

Lymph node, other

NST

−/−/−

40

III

23

45

Recurrent

Other

NST

+/+/−

15

NA

24

51

Recurrent

Lung, liver

Ductal

+/+/+

20

II

25

54

Recurrent

Other

NST

−/−/−

> 90

III

  1. a Acquired at diagnosis
  2. Abbreviations: ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, NA not available, NST no special type